| Name | Title | Contact Details |
|---|
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
For 27 years and counting, SLAM has been the most authentic brand in basketball storytelling. What started as a magazine in 1994 has now grown into a global lifestyle brand and multimedia property with 20-plus social channels, a burgeoning merchandise division and multiple franchise events annually. With over 16 million engaged followers across the globe, SLAM and its channels reach fans of the NBA, WNBA, college and high school, and the worlds of fashion, sneakers, gaming and more in a unique and trusted voice. The cover of SLAM remains the Holy Grail for basketball players; if you want to play in the NBA or WNBA, you want to be on the cover of SLAM.
American Nuclear Insurers (ANI) is a joint underwriting association created by some of the largest insurance companies in the United States. Our purpose is to pool the financial assets pledged by our member companies to provide the significant amount of property and liability insurance required for nuclear power plants and related facilities throughout the world.
In 2015, an important group of investors alongside a group of experienced professionals in the Reinsurance industry, acquired a majority interest in MBI Americas. Now, XS Global, a well-known regional MGA and Coverholder at Lloyds. The groups footprint and ambitions now encompass the underwriting space, utilizing strong synergies that exist between the groups core business strategy. Our unique structure provides us opportunities to deploy targeted reinsurance capacity both directly to corporates and to retail brokers via expert and locally based underwriters. We are proud to say we invest in talent and our team has proven skills, excellent access, and a proven track record for underwriting profitable business in the Latin America region and beyond.